People
The executive shuffle continues across the biopharma industry as companies shore up leadership needs with these Movers & Shakers.
New Movers & Shakers took over the roles of chief executive officer, chief financial officer, chief medical officer and more at companies including Scenic Biotech, Biofrontera and X4 Pharmaceuticals.
With the appointment of new CEOs, CMOs and CSOs, biopharma and life sciences organizations shuffled their leadership positions as Q3 comes to a close.
Kyverna Therapeutics filed its first IND application this week to test the efficacy and tolerability of KYV-101, a CAR-T therapy for lupus nephritis.
Verseon has acquired Edammo, an artificial intelligence-focused company, to deepen its own AI-based drug discovery platform. Financial terms were not disclosed.
The Biotechnology Innovation Organization, Passage Bio and Palisade Bio saw leadership shakeups at the top, while Maze Therapeutics, Cerecin and more appointed new chief medical officers.
Odyssey Therapeutics raised $168 million in a Series B financing round, which will be used to advance its portfolio of immunomodulators and oncology therapies.
The internet and “common wisdom” aren’t always right. Here are some of the top myths about three common conditions, and the truth from leading experts in their fields.
Biotechnology Innovation Organization, the world’s largest science and public advocacy organization, announced Monday it has tapped Rachel King to serve as interim President and CEO.
Biogen may have found its CEO in Mathai Mammen - former head of research and development in pharmaceuticals at Johnson & Johnson.
PRESS RELEASES